Introduction: With low rates of rejection with current immunosuppression consisting of steroids, mycophenolic acid and tacrolimus, the question arises whether induction offers any additional benefit in low-risk live renal transplant recipients . This study evaluated outcomes with and without induction in low-risk renal transplant recipients.
Aims and Objectives: Study of efficacy of induction (rejection rates), adverse effects (infection rates), patient and graft survival at 6 month had been compared between induction (IND) and non-induction (NO IND) group.
Material and methods:
Study design – retrospective observation study
Study period – March 2022 to July 2023
Study population – 50 low risk renal transplant recipients were included and divided into two groups –one received induction (ATG or Basiliximab) and another that did not.
Results: Incidence of rejection within 6 month did not differ (21% in IND vs 19.35 % in NO IND, p value -0.828) . Infection which requiring hospitalization were more common in IND group (78.90% IND vs 41.93% NO IND, p value -0.001). 31.6% patients in IND group vs 9.67% in NO IND group had more than 1 infection during 6 month period .CMV infection were also more common in IND group (15.7% IND vs 6.25% NO IND) .Average decline in GFR at 6 month was also higher in IND group (19.57± 21.63 IND vs 6.88±11.35 NO IND, p value -0.022) .Patient and overall graft survival at 6 month was comparable.


Conclusions: The study showed that increased incidence of infections, hospitalization and average decline in GFR in the IND group. The use of induction may be avoided in low-risk renal transplant recipients.